English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Psilocybin for Depression: What the Johns Hopkins Research Actually Found
A decade ago, the idea that a compound from a mushroom could be a serious candidate for treating major depression sounded fringe. Today it’s the subject of clinical trials at major research universities, the focus of FDA breakthrough therapy designations, and the quiet reason a lot of people in their thirties and forties are quietly googling “psilocybin retreat” at one in the morning. If you’re one of them, you probably want to know what the research actually says — not the headlines, not the hype. So let’s walk through it. Psilocybin, the psychoactive compound in what most people call magic mushrooms, has been studied on and off since the 1950s. The modern wave of research started small — pilot studies at Johns Hopkins, NYU, Imperial College London — many of them initially funded by private donors and nonprofits because federal money for psychedelic science was, for a long time, almost nonexistent. That early seed-funding mattered. It’s the reason we now have published data instead of just anecdotes. The mechanism question is the one researchers find most interesting, and it’s where the science has moved fastest. Brain imaging studies suggest psilocybin temporarily loosens the rigid patterns of communication that characterize the depressed brain. In people stuck in depression, certain networks — particularly the default mode network, which is heavily involved in self-referential thinking and rumination — tend to become overactive and locked-in. Psilocybin seems to quiet those entrenched circuits and, at the same time, open up new lines of communication between regions of the brain that don’t normally talk much. Researchers sometimes describe this as the brain entering a more flexible state. One Imperial College study described it as a kind of temporary “reset” of the depressive pattern. The metaphor isn’t perfect — nothing about the brain is that tidy — but it captures something real about why a single high-dose experience can sometimes shift moods that have been stuck for years. This is also why integration matters so much. The neuroplasticity window appears to stay open for days or weeks after the experience itself. What you do during that window — therapy, journaling, time in nature, honest conversations — seems to shape whether the changes hold. The most cited results come out of Johns Hopkins, where Roland Griffiths and colleagues ran landmark studies on psilocybin for psychological distress in cancer patients. A single high dose, paired with psychological support before and after, produced rapid and substantial reductions in depression and anxiety. The effects weren’t just statistically significant — they lasted. Six-month follow-ups still showed meaningful improvement in a majority of participants. A subsequent published trial extended those findings to people with major depressive disorder who didn’t have a terminal diagnosis. Two doses of psilocybin, embedded in roughly eleven hours of supportive therapy, outperformed what most antidepressant trials show. NYU’s parallel work with cancer patients reached similar conclusions. So did the larger Phase 2 trial run by COMPASS Pathways on treatment-resistant depression, where a single 25-milligram dose produced rapid antidepressant effects that were still measurable weeks later. These aren’t huge trials by pharmaceutical standards — we’re still talking about hundreds, not tens of thousands, of participants — but the signal is consistent enough that the FDA has granted psilocybin breakthrough therapy status. What does that mean for someone weighing a retreat? It means the underlying evidence is more substantial than skeptics often realize, and more provisional than enthusiasts often admit. Both things are true at once. The honest answer is that the current standard of care doesn’t work as well as we like to pretend. SSRIs help a real portion of people — but a real portion also don’t respond, or respond partially, or get unwanted side effects (numbing, weight gain, sexual dysfunction, the long taper if you ever try to come off). For people with treatment-resistant depression, the options shrink fast. Ketamine clinics have filled some of that gap. Psilocybin, if and when it’s approved for clinical use, is likely to fill more. Several public figures have spoken openly about their own depression in connection with funding or advocating for psilocybin research. Tim Ferriss is probably the best-known, having put significant personal money into the Johns Hopkins program and openly discussed his own struggles with suicidal ideation in his twenties. He’s not a clinician, and he’d be the first to say so, but his disclosure mattered because it modeled a kind of honesty most successful people avoid. What people in this space tend to share, regardless of their backgrounds, is the experience of feeling stuck — in a thought pattern, a behavior loop, a self-image — and the experience of psilocybin briefly making that stuckness negotiable. People expecting a recreational high are usually surprised. A therapeutic-dose psilocybin session, the kind used in the clinical trials, is closer to a six-hour interior excavation than a party. Participants typically lie down, wear eyeshades, and listen to a carefully curated music playlist while two trained facilitators sit nearby. There’s very little talking. The work happens inside. Common reports include: Griffiths’ research found that around seventy percent of participants rated their psilocybin experience as one of the five most meaningful of their lives. That’s a striking number — striking enough that careful scientists keep using the word “unprecedented.” It’s also why anyone considering this work should take it seriously, not casually. Outside the United States, psilocybin retreats operate legally in several countries — the Netherlands (where psilocybin-containing truffles remain legal), Jamaica, and a few others. If you’re researching options, the quality varies enormously. Some are deeply careful operations with medical screening, trained facilitators, and structured integration. Others are weekend parties dressed up with ceremony language. Telling them apart is the real work. A short list of questions worth asking before you book: A reputable program will answer all of these without defensiveness. If a retreat dodges the medical questions, that’s your answer. Depression is also one of the areas where preparation and integration arguably matter more than the experience itself — the dose isn’t a cure, it’s a window. What you do in the weeks after determines whether anything changes. Psilocybin isn’t for everyone. People with personal or family histories of psychosis, schizophrenia, or bipolar I are generally screened out of clinical trials for good reason. Certain heart conditions raise risks. And there’s the question of legal status — in most of the United States, psilocybin remains a Schedule I substance, with limited exceptions in Oregon and Colorado and a few decriminalized cities. The legal landscape is shifting, but it hasn’t shifted everywhere. Even for the right candidate, the experience can be hard. Sitting with old grief, watching a long-buried memory surface, feeling the full weight of a depressive pattern you’ve been numbing for years — none of that is pleasant in the moment. The research participants who reported the most benefit weren’t the ones who had the easiest sessions. They were the ones who let the difficult parts happen and then did the integration work afterward. If you’re someone who has tried the standard tools and still feels stuck, and you’re drawn to this for genuine reasons rather than novelty, it might be worth exploring further. For readers who want to take this further, a range of carefully vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, do it slowly, ask the uncomfortable questions, and treat the choice with the seriousness depression deserves.
Oregon's Psilocybin Market Explained: What the First Legal Psychedelic Program Means for Seekers
Picture this: a state inside the United States where you can, legally and openly, sit with a trained facilitator and take a measured dose of psilocybin mushrooms. Not in a back room. Not in a borrowed cabin in the woods. In a licensed service center, with paperwork, with insurance, with a guide who answered to a regulator. That state is Oregon, and the program it built has quietly reshaped what the conversation around psychedelics and psychedelic-assisted addiction recovery looks like in this country. If you've been reading about ayahuasca retreats in Peru, ibogaine clinics in Mexico, or master plants more broadly, Oregon is a different animal — and worth understanding before you book anything. It's the closest thing North America has to a regulated psilocybin experience, and the way companies have scrambled to enter that market tells you a lot about where psychedelic healing is actually going. Back in 2020, Oregon voters passed Measure 109. The measure didn't legalize mushrooms the way Colorado later legalized weed. It created something narrower and stranger: a supervised psilocybin services program, where licensed facilitators administer the substance to adults in licensed service centers. No take-home prescriptions. No dispensary model. You show up, you have your session, you integrate, you go home. The program took years to design. Rules around dosing, facilitator training, equity access, and product testing all had to be hammered out by a state advisory board. By the time the first service centers opened their doors, the country had its first legal, above-ground psilocybin offering. For people who'd been chasing this experience through underground circles or international retreats, it was a quiet earthquake. And here's where it gets interesting for anyone tracking the business side. Most U.S. psychedelics companies — the ones developing psilocybin and related compounds as FDA-approved medicines — explicitly refused to touch the Oregon program. Why? Because psilocybin is still a Schedule I substance federally. Participating in a state-legal but federally illegal market is a regulatory minefield, especially if you're trying to also run clinical trials with the FDA. One of the more telling moves in the early days came from a company called Field Trip Health. Field Trip ran two very different operations under one roof: a drug development arm working on novel psychedelic molecules, and a network of clinics offering ketamine-assisted therapy in the U.S. and Canada, plus a single psilocybin-focused clinic in Amsterdam where the legal landscape is friendlier. In 2022, the company announced it was splitting itself in two. The drug development side was rebranded Reunion Neuroscience and kept its Nasdaq listing. The clinic side stayed under the Field Trip Health & Wellness banner and moved to a Canadian exchange — the same kind of exchange that has allowed U.S. cannabis companies to trade publicly despite operating in federally illegal territory. The corporate logic was elegant. By cleaving the company in two, the clinic business could enter Oregon's psilocybin market without dragging the drug-development side into federal-law headaches. The Canadian exchange was the workaround. It's the same playbook cannabis used a decade earlier, and watching psychedelics companies adopt it tells you the industry has officially grown up — or grown cynical, depending on your view. Corporate news is fine for industry watchers, but you're probably here for a different reason. You're trying to figure out whether psilocybin, ayahuasca, or some other master plant could help you with depression, trauma, addiction, or a stuck life pattern that hasn't budged after years of conventional treatment. The Oregon model matters because it changes your options. Before Oregon, your legal-ish choices were narrow: Oregon added a fifth path: a domestic, regulated psilocybin session. That's huge for people who can't travel, can't afford a week-long international retreat, or want the legal protection of operating inside a sanctioned program. It's also limited. Oregon's service centers can't treat you as a patient in the medical sense — they're not allowed to diagnose, to bill insurance, or to claim psilocybin treats anything specifically. You're a client receiving a supervised experience, not a patient receiving a prescription. People often ask whether they should book Oregon or fly to the Amazon. The honest answer is that these are different experiences pointing at different things, and the right one depends on what you're after. None of this is medical advice. If you're on SSRIs, lithium, or have a personal or family history of psychosis or bipolar I, all of these need a serious medical conversation before you even start researching seriously. A lot of readers landing on articles like this aren't curious tourists. They're people who've tried everything for alcohol, opioids, stimulants, or behavioral addictions and watched it fail. The reason psychedelics keep entering this conversation is that the early clinical data, while still preliminary, is genuinely interesting. Psilocybin trials at Johns Hopkins showed striking abstinence rates in heavy smokers. Ayahuasca has a decades-long track record in Brazilian recovery communities. Ibogaine, despite serious cardiac risks that require medical screening, has produced what users describe as a single-shot interruption of opioid withdrawal that no other substance approaches. None of this is a guaranteed cure. People relapse. People have hard experiences. But the pattern of "one or two well-prepared sessions producing change that years of talk therapy didn't" shows up too often to dismiss. What the Oregon model proves is that the regulatory walls are crackable. Once a state shows you can run a legal psilocybin program without the sky falling, other states pay attention. Colorado followed with its own framework. More are circling. The shape of psychedelic-assisted recovery in 2026 looks meaningfully different from how it looked five years ago. If you're seriously considering plant medicine — Oregon psilocybin, an ayahuasca retreat, an ibogaine clinic, or something else — slow down. The single best predictor of a good outcome isn't the substance. It's the preparation, the facilitator, and the integration work afterward. Read everything. Talk to people who've done it. Get honest with yourself about why you're going and what you'd do if the experience surfaces things you weren't expecting. And vet the place. Ask about medical screening, facilitator training, what happens if you have a difficult moment at 3 a.m., what integration support looks like in the weeks after you go home. A good retreat or service center will answer these questions plainly. A sketchy one will dodge. If you want to compare options across countries, modalities, and price points, a range of curated ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time with the decision — the right container matters more than the calendar.
Ibogaine and Traumatic Brain Injury: What the Stanford Veterans Study Actually Found
Something unusual happened in a Stanford-led study published in Nature Medicine. Thirty Special Operations veterans — men carrying years of blast exposure, traumatic brain injuries, PTSD, depression, and in some cases active suicidal thoughts — flew to a clinic outside the United States, took a single dose of ibogaine paired with intravenous magnesium, and came back measurably different. Not slightly better. Not statistically nudged. Different in a way that the researchers described using effect sizes most psychiatric drugs never come within shouting distance of. If you've been quietly researching ibogaine for yourself or for someone you love — maybe a brother who came home from deployment and never really came home, maybe your own stuck pattern of addiction or depression — this study is worth understanding properly. Not the headline version. The actual one. Because ibogaine is powerful, it's serious, and the conversation around it has been a mess of hype and fear for decades. Let's slow down and look at what the Stanford team did, what they found, and what it means for anyone considering a psychedelic retreat involving this particular plant medicine. Ibogaine comes from the root bark of Tabernanthe iboga, a shrub native to Central Africa, where it's been used for generations in Bwiti spiritual ceremonies. In Western medicine, it's been studied mostly as a treatment for addiction — specifically opioid use disorder, where people have reported interrupted withdrawal and long stretches of sobriety after a single session. Pharmacologically, ibogaine is strange even by psychedelic standards. It touches NMDA, kappa and mu opioid, sigma, nicotinic, serotonin and dopamine systems, and it spikes neurotrophic factors like BDNF and GDNF that are linked to brain plasticity and repair. The experience itself isn't really a “trip” in the colorful, visionary sense people associate with ayahuasca or psilocybin. It's been called an oneirogen — a dream-inducer. Sessions last many hours, often well over a day, and participants describe long, lucid review states where memories, decisions, and unresolved material surface in a way that feels examined rather than chaotic. Think less fireworks, more long, brutally honest conversation with yourself. So why are veterans — particularly Special Operations veterans — seeking it out? Because the standard menu isn't working well enough. SSRIs, talk therapy, EMDR, exposure protocols: these help some people, but remission rates for combat-related PTSD hover stubbornly in the 20–40% range. Veterans account for roughly 20% of suicides in the U.S. while making up around 6.4% of the population. When the official toolbox keeps coming up short, people start looking elsewhere — and ibogaine has been quietly building a reputation in those circles for years. The protocol is called MISTIC — Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol. The magnesium part matters. Ibogaine's biggest historical safety concern is cardiac: it can prolong the Q–T interval, which in rare cases has led to fatal arrhythmias. Magnesium shortens the Q–T interval and has protective effects against drug-induced prolongation. Coadministering it isn't a cure-all, but the Stanford team built the protocol around the idea that supplementing magnesium during ibogaine dosing meaningfully reduces cardiac risk. Thirty male Special Operations veterans were enrolled. All had a history of TBI, most of it classified as mild and largely caused by repeated blast exposure. Half met criteria for major depressive disorder, nearly half for an anxiety disorder, and 23 of the 30 for PTSD. They received about 12 mg/kg of oral ibogaine alongside the magnesium protocol, with vital sign monitoring throughout. Treatment also included complementary therapies and integration support, which is worth noting — this wasn't ibogaine in isolation. The primary outcome was the World Health Organization Disability Assessment Schedule (WHODAS-2.0), a standard measure of how well someone functions in daily life. Secondary outcomes covered PTSD severity (CAPS-5), depression (MADRS), anxiety (HAM-A), suicidal ideation, and a battery of cognitive tests. Here's where the numbers start to look almost suspicious — until you read the methodology and realize the team measured carefully. And the safety picture? No unexpected or serious adverse events. No clinically meaningful Q–T prolongation. The most common side effects during dosing were headache, nausea, mild ataxia (wobbliness, basically) and intention tremor — all transient, all resolving within a day. Very. And the Stanford authors say so themselves. This was a prospective observational study, not a randomized controlled trial. There was no placebo arm. Participants knew they were getting ibogaine. They had self-selected into the treatment by traveling abroad to receive it, which means motivation and expectancy effects are baked into the results. The sample was 30 men, all from a specific Special Operations background, all with similar injury profiles. None of that invalidates the findings — but it does mean we can't extrapolate confidently to civilians, women, different TBI etiologies, or different psychiatric profiles. There's also the integration piece. MISTIC included complementary treatments and structured aftercare. Some unknown percentage of the benefit is likely attributable to the holding container around the ibogaine experience, not just the molecule itself. That's not a criticism — it's how serious psychedelic therapy works — but it matters for anyone imagining they could replicate this by simply dosing alone. What the study does do, convincingly, is signal that controlled trials are warranted and that the magnesium-coadministered protocol appears far safer than ibogaine's historical reputation suggests. That's a meaningful shift. Ibogaine remains a Schedule I substance in the United States, which is why this research had to be conducted on participants who traveled out of the country for treatment. Legal ibogaine clinics operate in Mexico, Costa Rica, Portugal, and a handful of other jurisdictions, with wildly varying levels of medical screening, cardiac monitoring, and aftercare. This variance is the single most important thing to understand before booking anything. If you're weighing a retreat, here's what to actually ask about — and what good answers look like: Ibogaine is not ayahuasca. It's not psilocybin. The experience is longer, more demanding on the body, and carries real cardiac considerations that the more commonly discussed plant medicines simply don't. It's also not for everyone — people with significant heart conditions, certain medications, or untreated substance dependencies that haven't been properly stabilized are poor candidates regardless of how badly they want relief. That said, what the Stanford work suggests — and what the broader field of psychedelic research keeps suggesting — is that some of these compounds, used carefully and within structured protocols, may do things conventional psychiatry has struggled to do for decades. Reduce PTSD. Lift treatment-resistant depression. Interrupt addiction. And, in this case, possibly help heal the cognitive and emotional consequences of brain injury that the medical system has largely written off as permanent. That's not a small claim, and it deserves the rigorous trials that are now being planned. For readers who want to keep exploring this thread responsibly, a curated selection of ibogaine and plant-medicine retreats can be browsed on our marketplace here. If you're reading this because someone you love is hurting, or because you are, the most useful thing this study offers isn't permission to rush. It's evidence that the door is wider than it looked, and that the people walking through it — with proper screening, proper monitoring, and proper integration — are sometimes finding what they came for.
Psychedelic Startups Worth Knowing About: A Plain-English Guide for Retreat-Seekers
Here's a question I get a lot from people sniffing around the edges of an ayahuasca or psilocybin retreat: Why is every other headline now about a psychedelic startup raising millions of dollars? Good question. Because if you're the kind of person seriously weighing whether plant medicine could help with depression, addiction, or that low hum of stuckness that no amount of journaling seems to fix, the answer matters. The money flowing into psychedelics is reshaping what's available, what's legal, and what kind of healing you can realistically access in the next few years. I'm going to walk you through what's actually happening in the startup world — without the jargon — and then bring it back to the only thing you probably care about: what this means for someone considering a retreat. Because here's the truth nobody in a pitch deck will tell you: the renaissance happening in labs and clinics is running parallel to, not replacing, the older tradition of ceremony, master plants, and the people who've been holding this work for generations. A few years ago, almost every psychedelic startup was a biotech company. They were trying to take psilocybin, MDMA, ibogaine, and various analogs through clinical trials, hoping to get them approved by regulators as medicines. That's still happening — and the trials are producing some genuinely jaw-dropping results, particularly for treatment-resistant depression and PTSD. But the landscape has gotten wider. Now there are companies building software to guide people through trip-like states without any substance at all. There are clinics offering legal, supervised ketamine therapy in dozens of US cities. There are AI platforms designing new psychedelic molecules from scratch. There are firms working on non-hallucinogenic versions of these compounds — yes, really — that aim to deliver the antidepressant punch without the eight-hour journey. And there are a handful of well-funded outfits trying to make synthetic mescaline, 5-MeO-DMT, and novel tryptamines into shelf-stable, prescribable medicine. Investors are betting this becomes a multi-hundred-billion-dollar industry within a decade. Whether you find that thrilling or a little nauseating probably depends on your relationship with the plants. Both reactions are reasonable. Roughly speaking, what's getting funded falls into four buckets. Knowing the difference helps you read the news without your eyes glazing over. Each of these affects you, the retreat-curious reader, in different ways. The drug developers will eventually make MDMA-assisted therapy and psilocybin therapy legal options in the US and Europe. The clinic networks already give you a legal entry point through ketamine. The tech companies are mostly noise, with the occasional gem. The discovery startups won't touch your life for years. Here's where I want to be honest with you. The biotech wave is exciting, but it isn't going to replace the experience of sitting in a maloca in the Peruvian Amazon, drinking ayahuasca brewed by someone whose grandmother brewed it, and confronting whatever it is you've been running from for twenty years. Those are different events. Both can heal. They're not the same thing. A clinical psilocybin trial gives you a precisely measured dose, a therapist in a clean room, eyeshades, and a curated playlist. A ceremony gives you icaros sung in Shipibo, a bucket, the sound of the jungle at three in the morning, and a worldview that treats the medicine as a teacher rather than a treatment. The clinical setting is safer in some ways and thinner in others. The ceremonial setting is richer in some ways and riskier in others. Anyone telling you one is strictly better than the other is selling something. What the startup boom does change for you: Because the industry is exploding, a lot of retreat centers have popped up that frankly shouldn't exist. Here's what I look for when someone asks me to vet a place — whether it's ayahuasca in the Amazon, psilocybin in Jamaica, or ibogaine for addiction in Mexico. The same skepticism applies to clinics, by the way. A ketamine clinic that doesn't include therapy alongside the infusion is mostly just selling you a dissociative experience. That can take the edge off depression for a few weeks. It probably won't change your life. I'll close with the thing I think gets lost in the investor-deck version of this story. The traditions around ayahuasca, peyote, San Pedro, iboga, and psilocybin mushrooms didn't show up because someone spotted a market. They've been refined over centuries, sometimes millennia, by people who understood these plants as relatives, not assets. The science is finally catching up to what those traditions already knew about consciousness, trauma, and addiction — which is a beautiful thing. But the catching-up is the point. The plants were here first. If you're researching a retreat right now, hold both truths at once. The clinical research is real and worth following. So is the older knowledge that says these are teachers, not treatments — and that what they teach you has to be lived out in your daily life or it slowly fades. The startups can build the delivery infrastructure. They can't build the courage it takes to actually sit down and drink the brew. For readers who want to take the next step, a range of vetted ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine, in whatever form you eventually meet it, will wait.
The Psychedelic Boom: What Could Actually Go Wrong With Plant Medicine
The psychedelics conversation has shifted fast. Five years ago, telling a coworker you were considering an ayahuasca retreat got you a raised eyebrow. Now it gets you a podcast recommendation and a friend-of-a-friend's WhatsApp contact in Costa Rica. Money is pouring in. Clinical trials keep making headlines. And somewhere between the Netflix documentaries and the LinkedIn evangelists, a quieter group of voices has been waving a flag — including many of the women who built the modern psychedelics field from the inside. Their message, more or less: slow down. Plant medicine and psychedelics can do remarkable things for addiction, depression, and trauma. They can also cause real harm when the setting is sloppy, the operators are dodgy, or the participant isn't ready. If you're researching a retreat right now, you deserve to hear both halves of that sentence — not just the inspirational one. Researchers and clinicians who've spent careers studying psilocybin, MDMA, and ayahuasca tend to talk about these compounds with a particular tone — respectful, a little wary, often awed. What they don't do is promise miracles. That's a tell worth paying attention to when you're scrolling through retreat websites that absolutely do promise miracles. The phrase “breathless enthusiasm” keeps coming up in conversations with senior figures in the space. The concern isn't that psychedelics don't work. It's that the cultural pendulum has swung so far toward hype that disappointment, harm, and political backlash are now baked into the trajectory. Anyone old enough to remember the 1960s knows how this story can end if the field overpromises. What does that mean for you, the person deciding whether to fly to Peru next spring? It means treating any retreat that sounds like a TED Talk with extra skepticism. A grounded facilitator will tell you what the medicine probably won't do, who shouldn't drink it, and what aftercare looks like. A hype merchant will tell you it changed their life and yours will too. One of those people is more likely to keep you safe. A lot of the public conversation about plant medicine runs on personal stories. Stories are powerful and they matter — but they aren't clinical evidence, and they're not a reliable guide to whether ayahuasca will help your particular brain. Researchers studying psychedelic-assisted therapy have been careful to distinguish what trials actually show from what enthusiasts claim on Twitter. Here's the honest landscape as of 2026. Psilocybin and MDMA have produced genuinely impressive results in trials for treatment-resistant depression and PTSD. Ibogaine has long-standing observational evidence for interrupting opioid addiction, though it carries serious cardiac risk. Ayahuasca has a smaller but growing research base around depression and trauma. None of it adds up to a guarantee. None of it replaces a competent psychiatrist or a real therapist. When you read a retreat's claims, look for hedged language and citations to actual studies. When you read absolutes — “cures addiction,” “heals all trauma,” “awakens your true self” — read them as marketing, because that's what they are. Master plants like ayahuasca, San Pedro, and iboga deserve more honesty than that, and so do you. One uncomfortable subplot of the psychedelic renaissance: the people most likely to benefit are often the least likely to afford the treatment. Approved psychedelic-assisted therapy in clinical settings can run thousands of dollars per session. Retreats abroad range from a few thousand to well over ten thousand for a week. Insurance coverage remains spotty at best. Some of the most pointed concerns from clinicians have focused on this gap. If psilocybin therapy becomes a $5,000 perk for the well-insured while people with the worst trauma, the worst addiction, and the fewest resources can't get near it, the field will have failed its own stated mission. There are organizations trying to close that gap. Progress is slow. For prospective retreat-goers, the access question shows up in a different form: budget honestly. Add up the retreat fee, flights, travel insurance, pre-retreat dieta groceries if you're prepping at home, and — critically — money for integration therapy afterward. That last line item is the one people forget. Integration is where the actual change happens, and a good therapist who understands psychedelics is not cheap. Let's name the harder stuff. Psychedelics can destabilize people. That's part of how they work — they loosen the grip of habitual thought patterns — but loosened thought patterns are not always pretty. People can surface trauma they didn't consciously remember. People can have psychotic episodes if there's an underlying vulnerability. People can leave a retreat more fragile than they arrived, especially if the facilitators aren't trained to catch them. There's also the deeply human problem of bad actors. The psychedelic space has had its own reckoning with abuse — facilitators crossing sexual and ethical boundaries with vulnerable participants in altered states. It happens more than the marketing suggests. The intimacy of the work, combined with the power asymmetry between guide and participant, creates exactly the conditions where predatory behavior can hide. Asking about a retreat's ethics policy, complaint procedure, and gender balance among facilitators is not paranoid. It's basic. And then there's the medication issue. Some psychedelic protocols require participants to taper off SSRIs, MAOIs, or other psychiatric medications beforehand. Doing this without proper medical supervision is dangerous on its own — and combining a taper with an intense ceremony, far from your normal support network, can leave people in genuinely difficult shape. Any retreat that tells you to stop your meds without involving a doctor is a retreat to walk away from. Okay, the warnings are on the table. Plenty of people still go, and plenty come back saying it was one of the most meaningful weeks of their lives. The difference between those people and the ones who come back worse is usually preparation and discernment. A short checklist of questions worth asking before you book: If a retreat answers those questions cleanly, you're probably looking at a serious operation. If they get defensive or evasive, you have your answer. Psychedelics aren't snake oil and they aren't sacrament-as-medicine that solves everything. They're powerful tools that, in the right hands and the right context, can crack open patterns — around addiction, depression, trauma, grief, stuck creative work — that years of conventional approaches couldn't budge. They can also waste your money or, worse, hurt you. Both things are true at once, and the people who refuse to hold both truths are the ones most likely to mislead you. If you're considering a retreat, take your time. Read first-person accounts from people who didn't have transformative experiences as well as the ones who did. Talk to a therapist before you book, not after. Be honest with yourself about why you're going — running toward something is different from running away from something, though both can be valid. For readers ready to look at specific options, a curated selection of ayahuasca and psychedelic plant-medicine retreats can be browsed on our marketplace here. The renaissance is real. So are the risks. Walking in with both eyes open is the whole game.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Is Cannabis a Psychedelic? What Psychiatrists Are Quietly Rethinking
Cannabis doesn’t usually get invited to the psychedelic dinner party. Mushrooms show up. Ayahuasca shows up. LSD wanders in late, talking about set and setting. Weed gets left on the porch with a bag of chips. But a small, persistent group of psychiatrists keep arguing it deserves a seat at the table — and the reasoning is more interesting than the stoner-meets-shaman cliché suggests. The premise is simple. Real psychedelics shift how you perceive the familiar. They strip the varnish off habit. Some researchers think cannabis — at certain doses, in certain people, in certain contexts — does a softer version of the same trick. Not the fireworks of a high-dose mushroom journey. More like a side door into the same room. This matters because the conversation around plant medicine, addiction, and master plants is widening fast. If cannabis genuinely belongs in that conversation, it changes how clinicians, retreat-goers, and policymakers think about an enormous, already-legal substance. If it doesn’t, the framing risks muddying the waters of real psychedelic-assisted therapy. Worth taking seriously either way. The case usually hinges on a clinical concept called dehabituation — the moment your brain stops auto-completing reality and actually looks at it again. You’ve felt this without any drug at all. The first morning of a vacation, when the light in a strange room hits you differently. The week after a breakup, when your own apartment looks like someone else’s. That fresh-eyes effect is what some psychiatrists believe cannabis can produce on demand, in lower-stakes form. Julie Holland, a New York psychiatrist who’s written extensively about psychoactive substances, has argued exactly this at psychedelic science conferences. Her phrasing — that cannabis can make everything old feel new again — is a tidy way of describing what therapists already chase in the consulting room. A lot of talk therapy is, at root, a perspective problem. You’re stuck in a loop. Something jolts the loop. The loop loosens. Insight follows. That’s also why psychiatry and psychedelics share a Latin root — psyche, the mind. Both act on it. They just work at different intensities, with different risks, and on different timelines. Calling cannabis psychedelic isn’t saying it’s the same as ayahuasca. It’s saying the mechanism — interruption of automatic perception — sits on a shared spectrum. The reason any of this is being discussed seriously now is the larger resurgence in psychedelic research. After decades of regulatory deep-freeze, psilocybin, MDMA, LSD, ayahuasca, and ibogaine are all back in clinical trials for depression, end-of-life anxiety, treatment-resistant PTSD, and addiction. Some of the results have been striking — striking enough that the FDA designated psilocybin a breakthrough therapy and MDMA-assisted therapy has moved through late-stage trials. Inside that wave, cannabis is the weird cousin. It’s been studied for chronic pain, nausea, sleep, and PTSD symptom management — Holland herself has worked as a medical monitor on a MAPS-led study examining marijuana for PTSD in veterans. But it sits in a category of its own at the DEA, which has historically made serious research painfully slow. So we’re left with a lot of anecdote, a growing pile of preliminary data, and very few clean answers. For anyone weighing a plant-medicine retreat, this matters in a specific way. Cannabis is sometimes folded into ceremonial work — in some traditions it’s used as a master plant in its own right, with dieta-like preparation, intention setting, and integration. In other traditions it’s seen as a distraction from deeper work. Both views have weight. Knowing which framing your facilitators hold is part of doing your due diligence. Here’s what the more measured proponents actually claim: None of that is the same as saying weed cures depression or replaces ayahuasca. It’s saying the plant has psychoactive properties that, used carefully, might be useful in a clinical or contemplative context. That’s a smaller, more defensible claim — and it’s the one worth taking forward. Cannabis also has a complicated relationship with mental health, and pretending otherwise serves nobody. The most comprehensive review of marijuana research to date — a sprawling National Academies report — found that heavier, more frequent use is associated with elevated risk of psychosis, social anxiety, and to a lesser degree, depression. The report couldn’t cleanly say whether cannabis causes those outcomes or whether people predisposed to them simply self-medicate more often. Probably some of both. The question is far from settled. What this means practically: cannabis is not a neutral tool. For some people it’s a quiet ally. For others, especially those with a family history of psychosis, heavy use can be genuinely destabilizing. The difference between the two camps isn’t always obvious until something cracks. And unlike a ceremonial psychedelic, cannabis is easy to use every day — which is where the dehabituation effect tends to invert. The thing that once made everything feel new becomes the thing you reach for to feel normal. That’s not insight. That’s dependence with extra steps. This is also the part of the conversation that gets skipped at parties. People love to hear that their daily habit might be secretly therapeutic. Fewer people love hearing that daily use probably blunts the very effect that made it interesting in the first place. If you’re researching ayahuasca, psilocybin, ibogaine, or another plant-medicine retreat, cannabis-as-psychedelic is mostly a tangent — but a useful one to think through before you go. Three practical points: The deeper point is that addiction and habituation exist on a continuum, and so do the tools we use to address them. Master plants like ayahuasca, iboga, and huachuma sit at the heavier end of that toolkit. Cannabis, used intentionally, may sit somewhere closer to the middle. Daily habit-use sits at the other end entirely — closer to the problem than to the solution. The honest answer is: slowly. Cannabis remains federally restricted in ways that make rigorous psychiatric study harder than it should be, even as more than half of U.S. states have legalized some form of access. The mismatch is producing a lot of street-level experimentation and not nearly enough clinical data. Meanwhile, classical psychedelics — psilocybin in particular — are racing ahead in the trial pipeline, and the regulatory frameworks built for them may eventually drag cannabis research forward in their wake. For now, the most useful posture is curious skepticism. Take seriously that thoughtful psychiatrists see something worth studying. Take equally seriously that the same plant, used differently, contributes to real mental-health harm. Both can be true. Most plants worth knowing are complicated. If exploring this terrain through a structured container appeals to you, a range of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — the plants will still be there next month, and the right retreat is almost never the one you booked in a hurry.
Psilocybin for Depression: How Psychedelics Rewire the Stuck Brain
Ask someone who's tripped on psilocybin what it felt like, and you'll often get answers that sound like bad poetry. They heard the color blue. A dropped fork made a shape. The afternoon light had a flavor. It's easy to write this off as drug-addled nonsense — until you sit with the neuroscience for a minute and realize the brain on a psychedelic is doing something genuinely strange, and possibly genuinely useful. This cross-wiring of senses — synaesthesia, if you want the clinical term — is one visible sign of something deeper happening underneath. The brain is, briefly, abandoning its usual rules about which regions talk to which. And that loosening is exactly what's drawing serious researchers to psychedelics as a treatment for depression, addiction, and the kind of mental ruts that years of standard care can't seem to budge. One of the more striking predictions in the field came years ago from David Nutt, who runs the neuropsychopharmacology unit in the division of brain sciences at Imperial College London. He stated flatly that he was certain psilocybin would become an accepted depression treatment within a decade. That timeline has been slipping forward and backward depending on which regulator you ask, but the direction of travel is unmistakable — clinical trials keep going, breakthrough-therapy designations keep landing, and the cultural conversation has shifted from fringe to front page of the science section. To understand why a researcher of his standing would stake a claim like that, it helps to look at what a healthy brain does on a normal Tuesday, and then at what a depressed brain does, and finally at what happens when psilocybin enters the picture. The story is more elegant than you'd think, and once you see it, the clinical interest stops looking like wishful thinking. Think of your brain as a city. Information moves between regions along circuits — call them highways. Some of those highways are jammed bumper-to-bumper around the clock. Others are barely used: weed-cracked back roads with maybe a car an hour. Most of your waking experience runs along the well-trafficked routes, because that's how the brain has learned to be efficient. Neuroimaging studies have mapped what changes when someone takes psilocybin. The pattern that emerges is roughly this: traffic gets redirected. Regions that don't usually communicate start swapping signals. Underused back roads light up. The dominant, heavily-used highways quiet down. The brain temporarily looks less like a commuter grid and more like a wide-open delta of new connections firing in unexpected directions. One researcher described it as a sense of lubrication — the cogs of the brain loosening and turning in ways they normally wouldn't. That's a strange image for a treatment, but it turns out to be a useful one. Because the problem with a depressed brain, increasingly, looks like the opposite of lubrication. It looks like cement. A defining feature of clinical depression — and of addiction, and of obsessive thinking — is overly strengthened connections in specific brain circuits. The regions involved in self-referential thought, mood, concentration, and the sense of who you are start firing on hair-triggers, again and again, in the same well-worn loops. The mental equivalent of West Los Angeles at rush hour, every day, with no detour available. This is partly why electroconvulsive therapy can still pull some people out of the deepest depressions — it physically disrupts that overcooked traffic pattern. It's a blunt instrument, but it works for some patients when nothing else has. The mechanism researchers care about isn't the electricity itself; it's the disruption. Nutt has put it bluntly: the depressed brain, the addicted brain, the obsessed brain — they all get locked into a pattern of processing driven by the frontal control center, and the person inside cannot un-depress themselves no matter how hard they try. Willpower doesn't fix a circuit. Therapy can help, medication can help, but for treatment-resistant cases, the rut just doesn't budge. Here's the part that matters. Psychedelics appear to do the same disruption ECT does, but with finesse — and with the patient awake, conscious, and able to remember what happened. The trip itself temporarily releases the brain from its usual circuits. The ruminations stop. The self-critical loop cuts out. People describe feeling, for the first time in years, like they can see around the wall they've been pressed against. And — this is the strange part — they often don't snap back. The trip ends after a few hours. But the relief, in a meaningful number of cases, persists. A small Imperial College trial gave psilocybin to patients with chronic, treatment-resistant depression — people who had tried medication after medication for years, sometimes decades. The study was designed mainly to confirm safety. But every participant reported significant symptom reduction at the one-week follow-up, and the majority were still doing better three months later. One dose. People who had been suffering for thirty years. That's not a marketing line; that's what the data showed. Nutt, who co-authored the paper, said it tells us the drug is doing something profound. The honest scientific answer to what, exactly, is still being worked out. Time for some appropriate hedging. The research base, while growing fast, is still small. A review of clinical trials on psychedelics from a stretch of twenty-five years found only six studies rigorous enough to draw conclusions from — the rest were too small, poorly controlled, or otherwise compromised. That number has grown since, but the field is still building its evidence base in real time. What the existing studies suggest is that ayahuasca, psilocybin, and LSD may be genuinely useful for treating drug dependence, anxiety, and mood disorders — particularly in patients who haven't responded to standard treatment. They may also be useful as research tools for understanding how psychiatric disorders work in the first place. That's a more modest claim than the headlines sometimes suggest, but it's also a more durable one. Researchers also can't yet say exactly what's happening inside a tripping brain at the molecular level. The best current theory is that the drug triggers a kind of snowball effect in how the brain processes information — similar, in a long-term sense, to how learning a musical instrument or a new language gradually rewires neural pathways. The trip itself is brief. The downstream changes seem to keep unfolding for weeks or months. If you're reading this because you're sitting with a depression that hasn't budged, or an addiction that keeps winning, or just a stuck pattern you can't think your way out of — the research is interesting, but it isn't a green light to book the first retreat that pops up on Instagram. A few honest considerations: None of this is meant to scare anyone off. It's meant to set expectations honestly, which is what I'd want from a friend in this space. The science genuinely is pointing toward something significant — possibly one of the most important shifts in mental health treatment in half a century. But the gap between “promising research” and “safe, well-run retreat” is real, and worth closing carefully. For readers who want to take the next step thoughtfully, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, give the decision the weight it deserves — the brain that's reading this sentence is the same one you'd be handing to a facilitator for the afternoon, and choosing well is most of the work.
Is Ibogaine a Mindfulness Pill? What the Iboga Experience Really Teaches
Someone asked me last year, half-joking, whether iboga was basically a mindfulness pill. The kind of thing you swallow when sitting on a cushion for ten years feels like too long a wait. I laughed. Then I thought about it for a week. Because the question, underneath the flippancy, points at something real. People who've sat with iboga — or its pharmaceutical cousin ibogaine — often describe an experience that sounds suspiciously close to what long-term meditators report: an unflinching look at their own conditioning, the loosening of compulsive patterns, a strange and uncomfortable clarity about who they've been. So is it a shortcut? Is it cheating? Is it even the same thing? I want to talk through this honestly, because I think the answer matters — especially if you're someone weighing whether to fly to Mexico or Costa Rica or Portugal and hand yourself over to a facilitator with a root bark and a stethoscope. Mindfulness, in the way it's taught now, usually means non-judgmental awareness of the present moment. You notice what's happening — thoughts, sensations, emotions — without grabbing at it or pushing it away. Done consistently over years, it tends to produce people who are less reactive, more present, better at noticing the gap between stimulus and response. That's the public-facing version. The deeper claim of contemplative traditions is bigger: that sustained practice reveals something about the nature of the self. That the “you” running the show is more constructed and more porous than it feels. Buddhist teachers have been pointing at this for two and a half millennia. It's not a productivity hack. It's a slow-motion ontological audit. Here's where iboga gets interesting. Because whatever else it does, it forces an audit. It just does it in fourteen hours instead of fourteen years. Iboga is the root bark of Tabernanthe iboga, a shrub native to Central Africa, used ceremonially for centuries by the Bwiti tradition in Gabon. Ibogaine is the principal alkaloid, extracted and used in clinical and retreat settings — most famously as a treatment for opioid and stimulant addiction. The two are related but not identical experiences. The whole-root ceremony tends to feel more textured and more guided by the plant's own logic; ibogaine in a clinic setting can feel more pharmacological, more medical. Either way, the experience is long. We're talking 12 to 36 hours of altered consciousness, with the most intense phase lasting maybe eight to twelve. People often describe two distinct stages. The first is sometimes called the “visionary” phase — a flood of memories, images, and what feels like a structured review of one's life. Not random imagery. Specific scenes, specific people, specific moments where you made a choice that set a pattern in motion. The second phase is quieter and stranger. The visions fade and you're left lying in the dark, mostly awake, watching your own mind work without the usual filters. This is the part that participants frequently describe as “meditation-like,” though it's a meditation you didn't sign up for and can't end early. Yes and no. Let me explain. The yes: iboga absolutely does produce states of detached, observational awareness. People come out of ceremonies describing days or weeks of unusual clarity — they can see their habitual reactions before they fire, they notice cravings without acting on them, they catch themselves in the middle of an old story and just… don't finish telling it. That's recognizably what mindfulness practice is supposed to deliver. There's emerging research suggesting ibogaine affects neuroplasticity in ways that may temporarily increase this kind of metacognitive capacity. The no: a pill that gives you the view for a month is not the same as a practice that gives you the legs to keep walking. Plenty of people have profound iboga experiences and slide right back into the patterns they thought they'd seen through. The experience hands you a map. It doesn't hand you the discipline to actually use it. This, by the way, is where iboga differs sharply from ayahuasca or psilocybin in the cultural conversation. Iboga isn't really sold as a journey. It's sold as a confrontation — particularly for people struggling with addiction. The marketing language around it is less “heart-opening” and more “interrupting a death spiral.” Which is closer to the truth. The reason ibogaine has built a reputation outside the broader psychedelic conversation is its effect on opioid dependence. People with heroin or fentanyl addictions report walking out of an ibogaine treatment with their withdrawal symptoms gone and their cravings dramatically reduced. This isn't a small thing. It's the closest thing the addiction field has to a chemical reset button — and that's why underground and offshore clinics have been running treatments for decades despite ibogaine being a Schedule I substance in the United States. But — and this is critical — ibogaine is not safe in the casual way some other plant medicines can be approached. It's cardiotoxic. It can cause fatal arrhythmias in people with undiagnosed heart conditions or certain medication interactions. Reputable clinics require EKGs, bloodwork, and medical supervision throughout. If you're researching ibogaine and a provider doesn't mention any of this, walk away. I mean it. A few things worth knowing if you're considering it: In the Amazonian traditions, ayahuasca isn't the only “master plant” — there's a whole pharmacopoeia of teachers, each said to offer a particular kind of instruction. Iboga sits in a parallel category from a different continent. The Bwiti tradition treats it not as a substance but as a teacher, an ancestor, something you enter into relationship with. That framing matters because it pushes back against the “mindfulness pill” idea. You don't take a master plant. You consult one. And the consultation, if you're paying attention, includes homework. The visions show you what's broken. The integration phase is when you decide whether to actually fix it. People who treat iboga as a one-shot fix tend to be disappointed. People who treat it as the beginning of a longer practice — therapy, meditation, lifestyle change, community — tend to be the ones whose lives actually shift. If you're researching iboga or ibogaine, start with brutal honesty about why. Are you looking for addiction recovery? A spiritual experience? Relief from depression that hasn't responded to anything else? Each of those points you toward different providers, different settings, different price points. A medical ibogaine clinic in Mexico is a very different proposition from a Bwiti-influenced ceremony in Costa Rica or Portugal. Both can be legitimate. Neither is interchangeable. Be skeptical of any provider promising transformation. Be more skeptical of one promising it without medical screening. And give yourself a serious think about what you'll do for the six months after — because that's the part that determines whether the experience becomes a turning point or a story you tell at parties. For readers wanting to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Whether iboga is a mindfulness pill or not, it's a serious tool — and the people who get the most out of it tend to be the ones who treat it that way from the first phone call.
Psychedelic Water Review: Does Kava Really Replace Your Evening Drink?
A friend of mine cracked open one of these cans at a backyard dinner last summer and someone immediately asked if she was tripping. She wasn’t. She was drinking what looked like a hard seltzer, was called Psychedelic Water, and contained roughly zero psychedelics. The name does a lot of heavy lifting — some of it useful, some of it misleading. I spent about a month using it the way the marketing suggests: as the thing in my hand at gatherings where everyone else was reaching for a margarita. I’m not strictly sober, I just have terrible hangovers and a low tolerance for the slow social erosion that comes with regular drinking. So this counted as a real experiment, not a stunt. Here’s what I learned about the drink, the ingredients, and the broader trend it rides on — including how it overlaps (and doesn’t) with the actual world of psychedelics and plant medicine. The headline ingredient is kava — a root from the South Pacific that islanders have used in social and ceremonial settings for centuries. Traditional kava is prepared by pounding or grinding the root and mixing it with water until you have something resembling muddy dishwater that tastes, frankly, the way it looks. The canned version is a much gentler product: kava extract, damiana leaf (a mild relaxant with a long history in Central America), green-tea extract for a small caffeine lift, and flavoring. Four flavors are in rotation — hibiscus lime, blackberry yuzu, oolong orange blossom, and prickly pear. Prickly pear is the one to start with. What kava does in the body is sedative-adjacent. It binds to GABA receptors, which is the same general pathway alcohol and benzodiazepines use, although kava is far gentler. You feel a softening of the edges. A loosening in the shoulders. Conversation feels easier without the sloppy disinhibition booze gives you. The National Institutes of Health notes that kava supplements have shown a small effect on reducing anxiety in clinical studies — modest, but real. One thing worth flagging up front: kava has been linked in rare cases to liver injury, especially when used heavily or combined with alcohol or certain medications. If you’re on prescription meds, drink regularly, or have any liver concerns, talk to a doctor before making this a habit. The occasional can at a dinner party is a different beast than daily use. Let’s clear up the obvious confusion first. Psychedelic Water is not psychedelic. There is no LSD, no psilocybin, no DMT, no mescaline. You will not see geometric patterns. You will not have an ego-dissolution experience in your kitchen. The name is a marketing choice — provocative, memorable, and arguably useful in the way it nudges the word “psychedelic” into ordinary supermarket vocabulary, but the can itself is closer to a fancy herbal tea than to anything you’d find at an ayahuasca retreat. What it actually feels like, for me, was a soft 20-minute onset of mild calm. A faint tingle on the tongue (kava does that — it’s a quirk of the active compounds called kavalactones). A small lift in mood that didn’t spike or crash. After two cans across an evening I felt loose-jawed and content. After three I felt slightly queasy and had a dull stomach ache, so I’d say two is the practical ceiling. The most useful comparison I can give: it sits somewhere between chamomile tea and a single glass of wine on the relaxation spectrum, minus the next-day fog. I slept well. I woke up sharp. I did not text anyone something I regretted. By the modest standards of a Tuesday night, that’s a win. Nonalcoholic-beverage sales jumped roughly a third year-over-year a couple of years back, and the curve has kept climbing since. The category that used to mean O’Doul’s and grape juice now includes adaptogenic sodas, hemp-derived seltzers, functional mushroom blends, and a whole subgenre of kava drinks. Psychedelic Water is one of the louder voices in that crowd, partly because of TikTok and partly because of the name. The motivations behind sober-curious living are more varied than the wellness narrative suggests. Yes, some people are quitting for health. But just as many cite productivity, mental clarity, sleep quality, and the simple math of not wanting to feel rotten on Saturday morning. Younger drinkers are also doing it for cost — alcohol is expensive — and for the fact that they’ve grown up watching the long-term damage it does to the people around them. That last one matters more than people admit. Alcohol is a pretty effective short-term anesthetic. Take it away and a lot of stuff surfaces — restlessness, sadness, the patterns you’ve been numbing for years. Some people find that uncomfortable and circle back. Others find it’s the doorway they didn’t know they were looking for. Here’s where it gets interesting for anyone who lands on a drink like this and starts wondering what else is out there. Kava is, in the broadest sense, a plant medicine. It’s a botanical with psychoactive properties used ceremonially by an indigenous culture for generations. That puts it in the same loose family as ayahuasca, San Pedro, peyote, and the other master plants — but the family is very, very loose. Kava sedates. Ayahuasca rearranges your sense of reality for six hours and shows you the contents of your own mind. They are not the same tool. I’ve sat in a number of ayahuasca ceremonies and interviewed facilitators across Peru, Costa Rica, and the Netherlands. The thing readers most often miss is that the “psychedelic” part of psychedelics isn’t about visuals or recreation — it’s about a temporary suspension of the usual mental machinery that lets you see your patterns, your trauma, your addiction, your grief, with unusual clarity. That’s why these medicines have become a serious conversation in addiction recovery, depression treatment, and PTSD therapy. Compounds like psilocybin and ibogaine are now in late-stage clinical trials for exactly those uses. A canned kava drink will not do any of that. What it might do, honestly and usefully, is start a conversation. If you’re someone who picks up a can called Psychedelic Water at a dinner party and finds yourself curious — really curious — about what the word actually means, that curiosity is worth following. Read about the Indigenous traditions. Read the Johns Hopkins research. Talk to people who’ve done the work. Don’t confuse a beverage with a ceremony. If you’re looking for a smarter thing to hold at a party, or a wind-down drink that won’t cost you Sunday morning, this category is worth exploring and Psychedelic Water is a reasonable entry point. Go in with realistic expectations. You’re buying a mild herbal relaxant in a stylish can, not a portal to anywhere. Pay attention to how your body responds, don’t mix it with alcohol or sedatives, and skip it entirely if you’re pregnant, on liver-sensitive meds, or drinking heavily already. And if the experiment leaves you genuinely interested in what plant medicines can do at the deeper end — addiction work, trauma work, the kind of inner inventory that actually changes a life — there’s a much larger world waiting. A growing range of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here, with facilitators and traditions worth taking seriously. Start with the can if you want. Just know that the can is the beginning of the question, not the answer.
Ibogaine Aftermath: Double Vision, Insomnia, and Body Temperature Swings Explained
Three days after a flood dose, you finally try to read something on your phone and the letters won't sit still. Sleep comes in 40-minute scraps. Your hands feel hot, your feet feel like ice, and your heart seems to be reporting from another time zone. Sound familiar? If you've recently sat with ibogaine — or you're researching what the recovery actually looks like before booking a retreat — this is the conversation nobody puts on the glossy brochure. Ibogaine is one of the most powerful tools in the plant medicine and psychedelic world for breaking addiction, particularly opioid dependence. It's also one of the most physiologically demanding. The aftermath can stretch out for weeks. Knowing what's normal, what's annoying, and what's a red flag matters. Most psychedelics clear your system in hours. Ibogaine doesn't play by those rules. The active alkaloid metabolizes into noribogaine, which binds to fat tissue and slowly releases back into circulation for days — sometimes weeks. That's part of what makes ibogaine so unusual for addiction work: the afterglow has a pharmacological tail. It's also why people report odd, lingering effects long after they assumed they'd be back to baseline. Noribogaine continues to nudge serotonin, dopamine, and opioid receptors. Your nervous system, meanwhile, has just been through something closer to a controlled crisis than a typical ceremony. The autonomic system — the one that runs your heartbeat, body temperature, digestion, and sleep — takes time to recalibrate. So when people show up in forums asking about double vision, insomnia, and thermoregulation chaos, they're not imagining things. These are documented post-ibogaine experiences. Across facilitator notes, harm-reduction guides, and the people I've talked with after their retreats, three after-effects come up over and over in the first one-to-four weeks: None of these are particularly fun. Most of them resolve on their own. But they're worth understanding so you can tell ordinary recovery from something that needs attention. During the ibogaine experience itself, eyes-closed visuals are part of the territory — the rapid film-reel of memories that the medicine is famous for. Afterwards, some people notice their eyes feel uncoordinated for days. Reading is hard. Phone screens blur. Driving feels unsafe. The mechanism is ataxia — a temporary disruption in the cerebellum's coordination of fine motor movement, including the muscles that aim your eyeballs. Ibogaine is famously ataxic during the acute phase (you'll have been walked to the bathroom by a facilitator for a reason), and residual cerebellar effects can hang around. Most people see this clear up within a week or two. If it's still happening at the four-to-six-week mark, that's the point to see a neurologist rather than another forum. This one surprises people. You'd think a medicine that knocks you flat for 24 hours would leave you ready to sleep for a month. Instead, the opposite often happens. Many people report two, three, even five days of almost no sleep after a flood dose, followed by weeks of choppy, fragmented rest. Part of this is noribogaine's stimulant-like profile slowly tapering off. Part of it is that opioid withdrawal — if that's why you came to ibogaine in the first place — has its own insomnia signature that doesn't fully resolve when the acute withdrawal does. And part of it is simply that your nervous system has been turned inside out and is still finding its footing. Practical things that help: keep caffeine to a minimum, get morning sunlight on your eyes, eat real meals at regular times, avoid heavy screens before bed, and accept that sleep will be weird for a while. Magnesium glycinate at night helps some people. Melatonin is hit-or-miss after ibogaine — some find it useful, others say it makes the dreams more intense than they want. Thermoregulation is run by your hypothalamus, which sits at the intersection of the endocrine and autonomic nervous systems. Both of those systems got rattled. So it's not strange that for a few weeks, your internal thermostat seems broken. People describe sweating through sheets, then shivering in a warm room twenty minutes later. Hands and feet that won't warm up. A face that flushes for no reason. Layered clothing is your friend. So is staying well hydrated with electrolytes — sodium, potassium, magnesium — because ibogaine is hard on minerals and the residual effects can show up as temperature swings. Most after-effects fade. Some don't, and a few are genuinely dangerous. The two that demand immediate medical attention are anything cardiac and anything that looks like a prolonged QT-interval issue. Ibogaine prolongs the QT interval, which means it can predispose the heart to a specific kind of arrhythmia called torsades de pointes. This is why reputable retreats screen for cardiac risk with an EKG, magnesium and potassium bloodwork, and a careful medication review before they'll give you a dose. The risk window for QT prolongation extends well past the ceremony itself — some studies suggest two weeks or more. Get medical care immediately if, in the weeks after ibogaine, you experience: The vast majority of people who do ibogaine in a properly screened, properly supervised setting come through without any of these. The minority who run into trouble usually skipped the screening — either because they treated at home with no medical backup, or because the operation they went to wasn't actually running the tests they claimed to. This is where the booking decision really lives, in my view. Anyone can hand you a capsule. What separates a credible ibogaine provider from a sketchy one is what happens before and what happens after. Things to ask before you put a deposit down: A serious operation will have answers ready. A sketchy one will get vague, defensive, or pivot to talking about how powerful the medicine is. The medicine is powerful. That's the point. It's also why the wrapper around the medicine — the screening, the supervision, the integration — matters more than the medicine itself. Here's the thing about ibogaine specifically, as compared with ayahuasca or psilocybin: the post-acute window stretches longer because of that fat-stored noribogaine slowly trickling back into your bloodstream. Many people describe two to six weeks of feeling unusually open, emotionally permeable, sometimes raw. The cravings for the substance you came to address may be remarkably quiet. Old emotional material may keep surfacing. This is the integration window. It's a gift if you use it. Therapy appointments scheduled in advance, a support group, a sober community, daily walks, journaling — the unglamorous infrastructure of recovery — work better in this window than at any other time. People who waste it tend to find the cravings creeping back. People who use it tend to describe ibogaine as the most useful single event in their recovery, even years later. If you're still researching whether this path is right for you, take your time. Read survivor accounts, read the harm-reduction literature, talk to people who've done it. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. The strange weeks after a flood dose aren't a sign that something went wrong. Usually they're a sign that something significant happened, and your body is still catching up. Treat that body kindly. Sleep when you can. Eat real food. Keep someone you trust in the loop. And if anything feels truly off — especially anything cardiac — don't tough it out. Get checked.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
